Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Temperature-controlled packaging solutions provider Nordic Cold Chain Solutions has introduced what it claims to be the first cold chain packaging solution tailored for transporting glucagon-like ...